Halozyme Therapeutics | HALO - Créances Commerciales





Créances Commerciales Changement Date
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amarin USD 126.83M 477K 2025-12
Amgen USD 9.14B 432M 2026-03
Baxter International USD 1.7B 310M 2026-03
Cara Therapeutics USD 2.24M 2.26M 2025-03
Cytokinetics USD 17.76M 15.96M 2025-12
DBV Technologies USD 15.97M 279K 2025-09
Eli Lilly USD 21.18B 1.02B 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Intrexon USD 1.02M 559K 2024-06
Ionis Pharmaceuticals USD 74M 8M 2026-03
MannKind USD 38.37M 20.98M 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Pfizer USD 15.84B 2.27B 2025-12
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
United Therapeutics USD 350.2M 52.5M 2025-12
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12